Evidence map›Paper›PMID 29791133›Full record

ArticleBiochemistry2018

Design, Construction, and Validation of Histone-Binding Effectors in Vitro and in Cells.

Stefan J Tekel, Cassandra Barrett, Daniel Vargas, Karmella A Haynes

Abstract read
In one paragraph

Article in Biochemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Mapping chromatin modifications at the single cell level.Development (Cambridge, England) · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Stefan J TekelSchool of Biological and Health Systems Engineering , Arizona State University , Tempe , Arizona 85287 , United States.
Cassandra BarrettSchool of Biological and Health Systems Engineering , Arizona State University , Tempe , Arizona 85287 , United States.
Daniel VargasSchool of Biological and Health Systems Engineering , Arizona State University , Tempe , Arizona 85287 , United States.
Karmella A HaynesSchool of Biological and Health Systems Engineering , Arizona State University , Tempe , Arizona 85287 , United States.ORCID 0000-0002-5975-577X
Arizona State University · US

Funding

Synthetic chromatin for cancer researchK01CA188164 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI HAYNES, KARMELLA ANN · 2014 to 2016
$474k
NCI NIH HHS K01 CA188164
6 · The paper itself

Abstract

Chromatin is a system of nuclear proteins and nucleic acids that plays a pivotal role in gene expression and cell behavior and is therefore the subject of intense study for cell development and cancer research. Biochemistry, crystallography, and reverse genetics have elucidated the macromolecular interactions that drive chromatin regulation. One of the central mechanisms is the recognition of post-translational modifications (PTMs) on histone proteins by a family of nuclear proteins known as "readers". This knowledge has launched a wave of activity around the rational design of proteins that interact with histone PTMs. Useful molecular tools have emerged from this work, enabling researchers to probe and manipulate chromatin states in live cells. Chromatin-based proteins represent a vast design space that remains underexplored. Therefore, we have developed a rapid prototyping platform to identify engineered fusion proteins that bind histone PTMs in vitro and regulate genes near the same histone PTMs in living cells. We have used our system to build gene activators with strong avidity for the gene silencing-associated histone PTM H3K27me3. Here, we describe procedures and data for cell-free production of fluorescently tagged fusion proteins, enzyme-linked immunosorbent assay-based measurement of histone PTM binding, and a live cell assay to demonstrate that the fusion proteins modulate transcriptional activation at a site that carries the target histone PTM. This pipeline will be useful for synthetic biologists who are interested in designing novel histone PTM-binding actuators and probes.

Indexed as

AnimalsChromatinEnzyme-Linked Immunosorbent AssayEpigenesis, GeneticHistonesHumansNuclear ProteinsProtein BindingProtein Processing, Post-TranslationalTranscription FactorsChromatinHistonesNuclear ProteinsTranscription Factors

Identifiers

PMID29791133
PMCPMC6370554
OpenAlexW2804735950

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.